Latest H5N1 clinical trials Stories
- Largest U.S.
- Triggered by ongoing and very successful multi-year collaboration TUBINGEN, Germany, July 1, 2014 /PRNewswire/ -- CureVac, a German clinical-stage biopharmaceutical company, today
VIENNA, June 12, 2014 /PRNewswire/ -- A prophylactic vaccine candidate against Chikungunya fever, developed by the Austrian biotech company Themis Bioscience GmbH induces
New research, by a team from Rhode Island Hospital (RIH), has uncovered a protein, or antigen, that is essential for malaria-causing parasites to escape from red blood cells. This protein also generates antibodies that can hinder the ability of malaria parasites to multiply, which may protect against severe malaria infection.
Results indicate vaccine generates an immune response against key toxins in volunteers and establish dosing for Phase III BOSTON, May 19, 2014 /PRNewswire/ -- Sanofi Pasteur, the vaccines
ROCKVILLE, Md., April 2, 2014 /PRNewswire-USNewswire/ -- Sanaria received the 2014 Vaccine Industry Excellence Award for the "Best Prophylactic Vaccine" at a ceremony held March 25 in Washington
DUBLIN, March 20, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/n8dfqv/china_influenza) has announced the addition of the "China
Somali Americans develop twice the antibody response to rubella from the current vaccine compared to Caucasians in a new Mayo Clinic study on individualized aspects of immune response.
Study shows vaccine provides protection against EV71-associated hand, foot and mouth disease in infants and young children BEIJING, Feb.
SINGAPORE and ZURICH, January 29, 2014 /PRNewswire/ -- Singapore's Agency for Science, Technology and Research (A*STAR) and Switzerland's Cytos Biotechnology AG today announced
- Sleep; the state or condition of being asleep.
- The state or condition of numbness of a part due to pressure on a nerve: as, the obdormition of a limb.